| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | BCAT1 |
| Uniprot No | P54687 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-386aa |
| 氨基酸序列 | MGSSHHHHHH SSGLVPRGSH MGSMKDCSNG CSAECTGEGG SKEVVGTFKA KDLIVTPATI LKEKPDPNNL VFGTVFTDHM LTVEWSSEFG WEKPHIKPLQ NLSLHPGSSA LHYAVELFEG LKAFRGVDNK IRLFQPNLNM DRMYRSAVRA TLPVFDKEEL LECIQQLVKL DQEWVPYSTS ASLYIRPTFI GTEPSLGVKK PTKALLFVLL SPVGPYFSSG TFNPVSLWAN PKYVRAWKGG TGDCKMGGNY GSSLFAQCEA VDNGCQQVLW LYGEDHQITE VGTMNLFLYW INEDGEEELA TPPLDGIILP GVTRRCILDL AHQWGEFKVS ERYLTMDDLT TALEGNRVRE MFGSGTACVV CPVSDILYKG ETIHIPTMEN GPKLASRILS KLTDIQYGRE ESDWTIVLS |
| 预测分子量 | 45 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于BCAT1重组蛋白的3篇参考文献示例(注：文献为假设性示例，实际引用时请核实真实来源)：
---
1. **标题**：*Expression and Structural Analysis of Recombinant Human BCAT1 for Enzymatic Studies*
**作者**：Zhang Y. et al.
**摘要**：研究报道了人源BCAT1重组蛋白在大肠杆菌中的高效表达与纯化，并通过X射线晶体学解析其三维结构，揭示了底物结合位点的关键残基，为酶活性调控提供结构基础。
---
2. **标题**：*Recombinant BCAT1 Drives Glioblastoma Proliferation via mTORC1 Signaling*
**作者**：Lee S. et al.
**摘要**：研究发现重组BCAT1蛋白通过增强支链氨基酸代谢激活mTORC1通路，促进胶质母细胞瘤细胞增殖，提示BCAT1作为潜在治疗靶点。
---
3. **标题**：*Kinetic Characterization of Recombinant BCAT1 in Neurotransmitter Synthesis*
**作者**：Wang X. et al.
**摘要**：通过体外酶活实验，分析重组BCAT1的动力学参数，证明其在谷氨酸和支链酮酸代谢中的双向催化作用，并探讨其对神经递质合成的潜在影响。
---
如需真实文献，建议使用PubMed或Web of Science检索关键词“BCAT1 recombinant protein”或“BCAT1 expression”。
**Background of BCAT1 Recombinant Protein**
Branched-chain amino acid transaminase 1 (BCAT1) is a pyridoxal 5′-phosphate (PLP)-dependent enzyme that catalyzes the reversible transamination of branched-chain amino acids (BCAAs: leucine, isoleucine, valine) to produce branched-chain α-keto acids (BCKAs) and glutamate. It plays a critical role in nitrogen metabolism, neurotransmitter synthesis, and cellular energy homeostasis. BCAT1 is predominantly expressed in the brain, placenta, and certain cancers, where its dysregulation is linked to neurological disorders, cancer progression, and metabolic reprogramming.
Recombinant BCAT1 protein is engineered using heterologous expression systems (e.g., *E. coli* or mammalian cells) to enable functional and structural studies. Its production involves cloning the BCAT1 gene into expression vectors, followed by purification via affinity tags (e.g., His-tag). The recombinant form retains enzymatic activity, making it valuable for investigating BCAA metabolism, enzyme kinetics, and substrate specificity.
Structurally, BCAT1 adopts a fold characteristic of the PLP-dependent transaminase family, with distinct substrate-binding and catalytic domains. Research highlights its role in modulating glutamate levels, influencing synaptic plasticity and excitotoxicity in neurological contexts. In cancer, BCAT1 overexpression is associated with tumor growth, metastasis, and resistance to therapies, likely through mTOR pathway activation or redox balance alterations.
BCAT1 recombinant protein is also utilized in drug discovery, serving as a target for inhibitors aimed at treating BCAT1-driven diseases. Additionally, it aids in diagnostic biomarker development for conditions like glioblastoma or neurodegenerative disorders. Ongoing studies focus on elucidating its tissue-specific regulation and interplay with metabolic pathways, underscoring its therapeutic and research significance.
×
